TY  - JOUR 
AU  - Lantero-Rodriguez, J.
AU  - Vrillon, A.
AU  - Fernández Lebrero, Aída
AU  - Ortiz-Romero, P.
AU  - Snellman, A.
AU  - Montoliu-Gaya, L.
AU  - Brum, W.S.
AU  - Cognat, E.
AU  - Dumurgier, J.
AU  - Puig-Pijoan, A.
AU  - Navalpotro-Gómez, I.
AU  - García-Escobar, G.
AU  - Karikari, T.K.
AU  - Vanmechelen, E.
AU  - Ashton, N.J.
AU  - Zetterberg, H.
AU  - Suárez-Calvet, M.
AU  - Paquet, C.
AU  - Blennow, K.
PY  - 2023
SN  - 1758-9193
UR  - http://hdl.handle.net/20.500.11940/21252
AB  - Background: Cerebrospinal fluid (CSF) p-tau235 is a novel biomarker highly specific of Alzheimer's disease (AD). However, CSF p-tau235 has only been studied in well-characterized research cohorts, which do not fully reflect the patient landscape found...
LA  - eng
KW  - Humans
KW  - Alzheimer Disease
KW  - Amyloid beta-Peptides
KW  - Amyloidosis
KW  - Biomarkers
KW  - Cognitive Dysfunction
KW  - tau Proteins
TI  - Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts
DO  - 10.1186/s13195-023-01201-0
T2  - Alzheimer's Research and Therapy
KW  - AS Santiago
KW  - CHUS
VL  - 15
ER  -